Prevention, Diagnosis, and Treatment of Hypertensive Heart Disease

Cardiology Clinics

Volumn 28, Issue 4, 2010, Pages 675-691

  Georgiopoulou, Vasiliki V ^a   Kalogeropoulos, Andreas P ^a   Raggi, Paolo ^a   Butler, Javed ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hypertensive heart disease; Prevention; Treatment

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EPLERENONE; HYDRALAZINE; IRBESARTAN; LOSARTAN; NITRATE; PERINDOPRIL; PLACEBO; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT; VERAPAMIL;

CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIASTOLIC DYSFUNCTION; DIET THERAPY; DRUG EFFICACY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; HYPERTENSIVE HEART DISEASE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MORTALITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SODIUM RESTRICTION; SYSTOLIC DYSFUNCTION; SYSTOLIC HYPERTENSION; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; COMBINED MODALITY THERAPY; DIET, SODIUM-RESTRICTED; ECHOCARDIOGRAPHY; HEART DISEASES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; WEIGHT LOSS;

EID: 77957723715     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2010.07.005     Document Type: Review

References (122)

1. Kannel W.B., Vasan R.S., Levy D. Is the relation of systolic blood pressure to risk of cardiovascular disease continuous and graded, or are there critical values?. Hypertension 2003, 42(4):453-456.
2. Lewington S., Clarke R., Qizilbash N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360(9349):1903-1913.
3. World Health Organization International statistical classification of diseases and related health problems 10th Revision. Diseases of the circulatory system Chapter IX. Available at:, Accessed January 20, 2010. http://apps.who.int/classifications/apps/icd/icd10online/.
4. Sugden P.H. Mechanotransduction in cardiomyocyte hypertrophy. Circulation 2001, 103(10):1375-1377.
5. Baines C.P., Molkentin J.D. STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 2005, 38(1):47-62.
6. Weber K.T. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000, 15(4):264-272.
7. Berk B.C., Fujiwara K., Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007, 117(3):568-575.
8. Wolf-Maier K., Cooper R.S., Banegas J.R., et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003, 289(18):2363-2369.
9. Levy D., Anderson K.M., Savage D.D., et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988, 108(1):7-13.
10. Kannel W.B., Dannenberg A.L., Abbott R.D. Unrecognized myocardial infarction and hypertension: the Framingham Study. Am Heart J 1985, 109(3 Pt 1):581-585.
11. Levy D., Larson M.G., Vasan R.S., et al. The progression from hypertension to congestive heart failure. JAMA 1996, 275(20):1557-1562.
12. Kalogeropoulos A., Georgiopoulou V., Kritchevsky S.B., et al. Epidemiology of incident heart failure in a contemporary elderly cohort: the Health, Aging, And Body Composition study. Arch Intern Med 2009, 169(7):708-715.
13. Butler J., Kalogeropoulos A., Georgiopoulou V., et al. Incident heart failure prediction in the elderly: the health ABC heart failure score. Circ Heart Fail 2008, 1(2):125-133.
14. Lloyd-Jones D., Larson M., Leip E., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002, 106(24):3068-3072.
15. World Health Report Reducing risks, promoting healthy life 2002, World Health Organization, Geneva (Switzerland), Available at:, Accessed February 1, 2010. http://www.who.int/whr/2002/en/whr02_en.pdf.
16. Reichek N., Devereux R.B. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 1981, 63(6):1391-1398.
17. Woythaler J.N., Singer S.L., Kwan O.L., et al. Accuracy of echocardiography versus electrocardiography in detecting left ventricular hypertrophy: comparison with postmortem mass measurements. J Am Coll Cardiol 1983, 2(2):305-311.
18. Okin P.M., Wright J.T., Nieminen M.S., et al. Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint. Am J Hypertens 2002, 15(8):663-671.
19. Lee D.K., Marantz P.R., Devereux R.B., et al. Left ventricular hypertrophy in black and white hypertensives. Standard electrocardiographic criteria overestimate racial differences in prevalence. JAMA 1992, 267(24):3294-3299.
20. Devereux R.B., Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977, 55(4):613-618.
21. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986, 57(6):450-458.
22. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18(12):1440-1463.
23. Qin J.X., Jones M., Travaglini A., et al. The accuracy of left ventricular mass determined by real-time three-dimensional echocardiography in chronic animal and clinical studies: a comparison with postmortem examination and magnetic resonance imaging. J Am Soc Echocardiogr 2005, 18(10):1037-1043.
24. Takeuchi M., Nishikage T., Mor-Avi V., et al. Measurement of left ventricular mass by real-time three-dimensional echocardiography: validation against magnetic resonance and comparison with two-dimensional and m-mode measurements. J Am Soc Echocardiogr 2008, 21(9):1001-1005.
25. Grothues F., Smith G.C., Moon J.C., et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002, 90(1):29-34.
26. Edvardsen T., Rosen B.D., Pan L., et al. Regional diastolic dysfunction in individuals with left ventricular hypertrophy measured by tagged magnetic resonance imaging-the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2006, 151(1):109-114.
27. Raman S.V., Shah M., McCarthy B., et al. Multi-detector row cardiac computed tomography accurately quantifies right and left ventricular size and function compared with cardiac magnetic resonance. Am Heart J 2006, 151(3):736-744.
28. Schlosser T., Mohrs O.K., Magedanz A., et al. Assessment of left ventricular function and mass in patients undergoing computed tomography (CT) coronary angiography using 64-detector-row CT: comparison to magnetic resonance imaging. Acta Radiol 2007, 48(1):30-35.
29. Schepis T., Gaemperli O., Koepfli P., et al. Comparison of 64-slice CT with gated SPECT for evaluation of left ventricular function. J Nucl Med 2006, 47(8):1288-1294.
30. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002, 288(14):1723-1727.
31. Sources of sodium among the US population, 2005-06 Available at:, Accessed February 10, 2010. http://riskfactor.cancer.gov/diet/foodsources/sodium/#tables.
32. US Department of Health and Human Services, Centers for Disease Control and Prevention Atlanta (GA). Physical activity and health: a report of the surgeon general Available at:, Accessed February 11, 2010. http://www.cdc.gov/nccdphp/sgr/ataglan.htm.
33. Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention: National Fruit and Vegetable Program Available at:, Accessed February 10, 2010. http://apps.nccd.cdc.gov/5ADaySurveillance/.
34. Whelton P.K., He J., Appel L.J., et al. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002, 288(15):1882-1888.
35. Collins R., Peto R., MacMahon S., et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990, 335(8693):827-838.
36. Kostis J.B., Davis B.R., Cutler J., et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997, 278(3):212-216.
37. Moser M., Hebert P.R. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996, 27(5):1214-1218.
38. Jackson R., Lawes C.M., Bennett D.A., et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005, 365(9457):434-441.
39. Ferrucci L., Furberg C.D., Penninx B.W., et al. Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile. Circulation 2001, 104(16):1923-1926.
40. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497.
41. Giles T.D., Berk B.C., Black H.R., et al. Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) 2005, 7(9):505-512.
42. Mancia G., De Backer G., Dominiczak A., et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25(6):1105-1187.
43. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
44. Falkner B., Gidding S.S., Portman R., et al. Blood pressure variability and classification of prehypertension and hypertension in adolescence. Pediatrics 2008, 122(2):238-242.
45. Geleijnse J.M., Kok F.J., Grobbee D.E. Impact of dietary and lifestyle factors on the prevalence of hypertension in Western populations. Eur J Public Health 2004, 14(3):235-239.
46. Neter J.E., Stam B.E., Kok F.J., et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003, 42(5):878-884.
47. Stevens V.J., Obarzanek E., Cook N.R., et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001, 134(1):1-11.
48. Blair S.N., Goodyear N.N., Gibbons L.W., et al. Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA 1984, 252(4):487-490.
49. Appel L.J., Moore T.J., Obarzanek E., et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997, 336(16):1117-1124.
50. Sacks F.M., Svetkey L.P., Vollmer W.M., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001, 344(1):3-10.
51. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997, 157(6):657-667.
52. Appel L.J., Espeland M.A., Easter L., et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 2001, 161(5):685-693.
53. Dietary guidelines for Americans 2005, US Department of Health and Human Services, US Department of Agriculture, Washington, DC, Available at:, Accessed February 11, 2010. http://www.health.gov/dietaryguidelines/dga2005/document/pdf/dga2005.pdf, 6th edition.
54. Centers for Disease Control and Prevention (CDC) Application of lower sodium intake recommendations to adults-United States, 1999-2006. MMWR Morb Mortal Wkly Rep 2009, 58(11):281-283.
55. American Heart Association IOM Committee on Strategies to Reduce Sodium Intake March 30, 2009. Available at:, Accessed February 10, 2010. http://americanheart.org/downloadable/heart/1240425252727AHA%2520Statement%2520to%2520IOM%2520on%2520Strategies%2520to%2520Reduce%2520Sodium%2520Intake%2520033009.pdf.
56. Frohlich E.D., Chien Y., Sesoko S., et al. Relationship between dietary sodium intake, hemodynamics, and cardiac mass in SHR and WKY rats. Am J Physiol 1993, 264(1 Pt 2):R30-R34.
57. de Simone G., Devereux R.B., Camargo M.J., et al. Influence of sodium intake on in vivo left ventricular anatomy in experimental renovascular hypertension. Am J Physiol 1993, 264(6 Pt 2):H2103-H2110.
58. de Simone G., Devereux R.B., Camargo M.J., et al. Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition. Am J Hypertens 1996, 9(3):216-222.
59. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42(6):1206-1252.
60. Verdecchia P., Staessen J.A., Angeli F., et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009, 374(9689):525-533.
61. McNair A., Rasmussen S., Nielsen P.E., et al. The antihypertensive effect of prazosin on mild to moderate hypertension, changes in plasma volume, extracellular volume and glomerular filtration rate. Acta Med Scand 1980, 207(5):413-416.
62. Wilner K.D., Ziegler M.G. Effects of alpha 1 inhibition on renal blood flow and sympathetic nervous activity in systemic hypertension. Am J Cardiol 1987, 59(14):82G-86G.
63. Matsui Y., Eguchi K., Shibasaki S., et al. Effect of doxazosin on the left ventricular structure and function in morning hypertensive patients: the Japan Morning Surge 1 study. J Hypertens 2008, 26(7):1463-1471.
64. Klingbeil A.U., Schneider M., Martus P., et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115(1):41-46.
65. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359(9311):995-1003.
66. Wachtell K., Lehto M., Gerdts E., et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005, 45(5):712-719.
67. Fogari R., Mugellini A., Destro M., et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006, 47(1):46-50.
68. Gonzalez A., Lopez B., Ravassa S., et al. Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. Hypertension 2002, 39(1):75-80.
69. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288(23):2981-2997.
70. Wiysonge C.S., Bradley H., Mayosi B.M., et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007, 1. CD002003.
71. Bangalore S., Wild D., Parkar S., et al. Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol 2008, 52(13):1062-1072.
72. Verdecchia P., Angeli F., Cavallini C., et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J 2009, 30(6):679-688.
73. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359(23):2417-2428.
74. Borzecki A.M., Oliveria S.A., Berlowitz D.R. Barriers to hypertension control. Am Heart J 2005, 149(5):785-794.
75. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005, 353(5):487-497.
76. Mathew J., Sleight P., Lonn E., et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001, 104(14):1615-1621.
77. Okin P.M., Devereux R.B., Harris K.E., et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med 2007, 147(5):311-319.
78. Okin P.M., Devereux R.B., Jern S., et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004, 292(19):2343-2349.
79. Devereux R.B., Dahlof B., Gerdts E., et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004, 110(11):1456-1462.
80. Okin P.M., Hille D.A., Kjeldsen S.E., et al. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. Am J Hypertens 2010, 23(7):786-793.
81. Agabiti-Rosei E., Trimarco B., Muiesan M.L., et al. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2005, 23(5):1091-1098.
82. Bella J.N., Palmieri V., Wachtell K., et al. Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. J Hum Hypertens 2004, 18(6):411-416.
83. Muller-Brunotte R., Edner M., Malmqvist K., et al. Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy. J Hypertens 2005, 23(3):633-640.
84. Terpstra W.F., May J.F., Smit A.J., et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001, 19(2):303-309.
85. Brilla C.G., Funck R.C., Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000, 102(12):1388-1393.
86. Diez J., Querejeta R., Lopez B., et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002, 105(21):2512-2517.
87. Ciulla M.M., Paliotti R., Esposito A., et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation 2004, 110(5):552-557.
88. Warner J.G., Metzger D.C., Kitzman D.W., et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol 1999, 33(6):1567-1572.
89. Setaro J.F., Zaret B.L., Schulman D.S., et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990, 66(12):981-986.
90. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362(9386):777-781.
91. Ahmed A., Rich M.W., Fleg J.L., et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006, 114(5):397-403.
92. Cleland J.G., Tendera M., Adamus J., et al. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006, 27(19):2338-2345.
93. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359(23):2456-2467.
94. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT) Available at:, Accessed June 29, 2010. http://clinicaltrials.gov/ct2/show/NCT00094302.
95. Paulus W.J., Tschope C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28(20):2539-2550.
96. Shah S.J., Gheorghiade M. Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA 2008, 300(4):431-433.
97. Jessup M., Abraham W.T., Casey D.E., et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119(14):1977-2016.
98. McAlister F.A., Wiebe N., Ezekowitz J.A., et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009, 150(11):784-794.
99. Wong M., Staszewsky L., Latini R., et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol 2004, 43(11):2022-2027.
100. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362(9386):767-771.
101. Pitt B., Bakris G., Ruilope L.M., et al. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008, 118(16):1643-1650.
102. Georgiopoulou V.V., Kalogeropoulos A.P., Giamouzis G., et al. Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy. Circ Heart Fail 2009, 2(2):90-97.
103. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986, 314(24):1547-1552.
104. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325(5):303-310.
105. Carson P., Ziesche S., Johnson G., et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999, 5(3):178-187.
106. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351(20):2049-2057.
107. Knight B.P., Goyal R., Pelosi F., et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol 1999, 33(7):1964-1970.
108. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352(3):225-237.
109. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346(12):877-883.
110. Kadish A., Dyer A., Daubert J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004, 350(21):2151-2158.
111. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002, 346(24):1845-1853.
112. McAlister F.A., Stewart S., Ferrua S., et al. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004, 44(4):810-819.
113. Paterna S., Gaspare P., Fasullo S., et al. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?. Clin Sci (Lond) 2008, 114(3):221-230.
114. Experience from controlled trials of physical training in chronic heart failure Protocol and patient factors in effectiveness in the improvement in exercise tolerance. European Heart Failure Training Group. Eur Heart J 1998, 19(3):466-475.
115. McKelvie R.S., Teo K.K., Roberts R., et al. Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). Am Heart J 2002, 144(1):23-30.
116. Hambrecht R., Niebauer J., Fiehn E., et al. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. J Am Coll Cardiol 1995, 25(6):1239-1249.
117. Piepoli M.F., Davos C., Francis D.P., et al. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004, 328(7433):189.
118. O'Connor C.M., Whellan D.J., Lee K.L., et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009, 301(14):1439-1450.
119. Flynn K.E., Pina I.L., Whellan D.J., et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009, 301(14):1451-1459.
120. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006, 48(4):854-906.
121. Zipes D.P., Camm A.J., Borggrefe M., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006, 48(5):e247-e346.
122. Rosendorff C., Black H.R., Cannon C.P., et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007, 115(21):2761-2788.